Oral Presentations 7- TDM of Biologics

08:30 • 647 • Quantifying the Combined Impact of Target (TNF) Binding and Anti-Drug Antibodies on Infliximab Pharmacokinetics: An Integrated “TMDD–ADAMDD” framework > D. David TERNANT 08:43 • 624 • Pharmacokinetics of rituximab and progression free survival for interstitial lung diseases: a PK-TtE model from EVER-ILD trial. > C. Cynthia Flambard 08:56 • 398 • EVsDNA 5hmC Signatures Predict Infliximab Response Beyond Drug Exposure: A Multi-Omics Precision Therapeutics Strategy in IBD > H. Huibo Li 09:09 • 534 • Interpretable Machine Learning–Driven Exposure–Response Modeling to Optimize Infliximab Precision Dosing in Inflammatory Bowel Disease > H. Huibo Li 09:22 • 627 • Methotrexate Polyglutamates reduce Adalimumab Immunogenicity in Axial Spondyloarthritis: A prospective study > B. Bechara Saade 09:34 • 501 • Evolution of Infliximab therapy in Inflammatory Bowel Disease: from empirical to precision medicine > N. Núria Padullés-Zamora 09:46 • 169 • Model-based Evaluation of Individualized and Cost-Saving Dosing Strategies for Pembrolizumab > Y. Yan Wang